Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine

Molecular Therapy

Volumn 15, Issue 2, 2007, Pages 411-421

  Yan, Jian ^a   Yoon, Hanna ^a   Kumar, Sanjeev ^a   Ramanathan, Mathura P ^a   Corbitt, Natasha ^a   Kutzler, Michele ^a   Dai, Anlan ^a   Boyer, Jean D ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; EY2E1 B ANTIGEN; IMMUNOGLOBULIN E; RNA; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; CROSS REACTION; DRUG DESIGN; DRUG POTENCY; EPITOPE MAPPING; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PHYLOGENY; TRANSGENIC MOUSE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENES, ENV; HIV ANTIGENS; HIV-1; HLA-A2 ANTIGEN; IMMUNITY, CELLULAR; IMMUNIZATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; MUS MUSCULUS;

EID: 33846301454     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300036     Document Type: Article

References (43)

1. Mansky, LM and Temin, HM (1995). Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094.
2. Marin, M, Rose, KM, Kozak, SL and Kabat, D (2003). HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9: 1398-1403.
3. Sheehy, AM, Gaddis, NC and Malim, MH (2003). The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
4. Gao, F et al. (2005). Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 79: 1154-1163.
5. Scriba, TJ et al. (2005). Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences. Vaccine 23: 1158-1169.
6. Doria-Rose, NA et al. (2005). Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 79: 11214-11224.
7. Gao, F et al. (2004). Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 3: S161-S168.
8. Mullins, JI, Nickle, DC, Heath, A, Rodrigo, AG and Learn, GH (2004). Immunogen sequence: The fourth tier of AIDS vaccine design. Expert Rev Vaccines 3: S151-S159.
9. Nickle, DC et al. (2003). Consensus and ancestral state HIV vaccines. Science 299: 1515-1517.
10. Derdeyn, CA et al. (2004). Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019-2022.
11. Chohan, B et al. (2005). Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 79: 6528-6531.
12. Pickora, C, Wittish, C and Desrosiers, RC (2005). Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4. J Virol 79: 12575-12583.
13. Girard, MP, Mastro, TD and Koff, WC (2003). Vaccine. Elsevier Publications Philadelphia, PA, pp 1219-1258.
14. McMichael, AJ and Hanke, T (2002). The quest for an AIDS vaccine: Is the CD8+ T-cell approach feasible? Nat Rev Immunol 2: 283-291.
15. Andre, S et al. (1998). Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72: 1497-1503.
16. Deml, L et al. (2001). Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 gag protein. J Virol 75: 10991-11001.
17. Schneider, R, Campbell, M, Nasioulas, G, Felber, BK and Pavlakis, GN (1997). Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 71: 4892-4903.
18. Muthumani, K et al. (2003). Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. Virology 314: 134-146.
19. Yang, JS et al. (2001). Induction of potent Th1-Type immune responses from a novel DNA vaccine for West Nile Virus New York Isolate (WNV-NY1999). J Infect Dis 184: 809-816.
20. Berlioz-Torrent, C et al. (1999). Interactions of the cytoplasmic domains of human and simian retrovial transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J Virol 73: 1350-1359.
21. Bultmann, A, Muranyi, W, Seed, B and Haas, G (2001). Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression. J Virol 75: 5263-5276.
22. Buchacher, A et al. (1994). Generation of human monoclonal antibodies against HIV-1 proteins: Electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10: 359-369.
23. Trkola, A et al. (1996). Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100-1108.
24. Ugen, KE (1993). Generation of antibodies against the aminoterminus of gp120 that elicit antibody-dependent cellular cytotoxicity In: Refaeli Y, Ziegner U, Agadjanan M, Satre MA, Srikantan V, Wang B, Sato T, Williams WV, Weiner DB (eds). Vaccines 93. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, pp 215-221.
25. Rencher, SD and Hurwitz, JL (1997). Effect of natural HIV-1 envelope V1-V2 sequences diversity on the binding of V3-specific and non-V3-specific antibodies. J Acquir Immune Defic Syndr Hum Retrovirol 16: 69-73.
26. Almond, N et al. (1995). Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345: 1342-1344.
27. Berman, PW et al. (1996). Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis 173: 52-59.
28. Boyer, J et al. (1997). Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 3: 526-532.
29. Daniel, MC, Kirchhoff, F, Czajak, SC, Sehgal, S and Desrosiers, RC (1992). Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258: 1938-1941.
30. Gaschen, B et al. (2002). Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
31. Kolchinsky, P, Kiprilov, E and Sodroski, J (2001). Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 75: 2041-2050.
32. Puffer, BA et al. (2002). CD4 independent of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 76: 2595-2605.
33. Edwards, TG et al. (2001). Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J Virol 75: 5230-5239.
34. Zhang, L et al. (1998). Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol 72: 9307-9312.
35. Bjorndal, A et al. (1997). Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 71: 7478-7487.
36. Tersmette, M et al. (1989). Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. J Virol 63: 2118-2125.
37. Connor, RI and Ho, DD (1994). Transmission and pathogenesis of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 10: 321-323.
38. Wang, WK, Dudek, T, Essex, M and Lee, TH (1999). Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Proc Natl Acad Sci USA 96: 4558-4562.
39. Weaver, EA et al. (2006). Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group M consensus Env immunogen. J Virol 80: 6745-6756.
40. Thompson, JD, Gibson, TJ, Plewniak, F, Jeanmougin, F and Higgins, DG (1997). The ClustalX windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.
41. Kumar, S et al. (2006). Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct. DNA Cell Biol 25: 383-392.
42. Newberg, MH et al. (1996). Important of MHC class I alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J Immunol 156: 2473-2480.
43. Boyer, JD et al. (1997). DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees. J Infect Dis 176: 1501-1509.